Michael J. Holtzman, MD, has received close to $7.5 million in total funding for research aimed at developing stem cell-based treatments for chronic obstructive pulmonary disease (COPD), asthma, and other disorders. Holtzman’s research at Washington University School of Medicine in St. Louis identified a subset of stem…
The Dorney-Koppel Family Charitable Foundation put chronic obstructive pulmonary disease in the spotlight, leading the educational grand challenge at the recent Stanford Medicine X | CHANGE 2019 conference. This year’s educational challenge, which lasts until December, will explore and discuss solutions to five critical problems related to chronic…
The RheOx system for the treatment of chronic bronchitis has received the CE mark, an indication that it has met high health, safety, and environmental protection requirements, in the European Union. Developed by Gala Therapeutics, the RheOx system is a minimally invasive tool used to perform a procedure called…
Priority Health will cover Pulmonx’s Zephyr Endobronchial Valve device as a non-surgical treatment option for severe emphysema, a severe form of chronic obstructive pulmonary disease (COPD). The insurer’s new coverage policy is specific to the device marketed by Pulmonx. With this Priority Health decision, some 30 million U.S. residents with…
The use of electronic cigarettes, more commonly known as vaping, triggers cellular responses in the lungs similar to those elicited by smoking tobacco cigarettes, which may place e-cigarette users at risk of developing chronic lung diseases, a study says. Results from the study, “Chronic E-Cigarette Use Increases Neutrophil Elastase…
Kali-Extracts has launched a dedicated website for its cannabis-based  therapy candidate, RespRX, for chronic obstructive pulmonary disease (COPD) and related disorders. The company announced that as it moves toward the goal of federal approval of RespRX, its website will be updated regularly with information about the applications’ status,…
The triple combination therapy Breztri Aerosphere has successfully achieved its primary goal of reducing the rate of exacerbations — bouts of breathlessness — in people with chronic obstructive pulmonary disease (COPD) in the ongoing ETHOS trial, AstraZeneca announced.
Patients with chronic obstructive pulmonary disease (COPD) who are experiencing severe exacerbations should receive noninvasive ventilation, regardless of factors such as older age, low body mass index (BMI), left heart dysfunction, and abnormal levels of gases in the blood, a study suggests. Researchers in the study found that these…
Medical device company Adherium and informatics company Summatix are teaming up to help clinicians provide the best possible care for people with asthma and chronic obstructive pulmonary disease (COPD). Through this partnership, Adherium will gain access to Summatix’s regulated data platform…
Nuvaira, a medical device company, announced the upcoming publication of several scientific studies detailing the findings of clinical trials that assessed the safety and effectiveness of its Targeted Lung Denervation (TLD) therapy in patients with chronic obstructive pulmonary disease (COPD). Nuvaira’s proprietary TLD therapy works to disrupt pulmonary…
Get regular updates to your inbox.